News and Announcements
Proteomics International’s PromarkerD Test Latest Comprehensive Update
- Published April 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Proteomics International Laboratories Ltd (ASX: PIQ) (PILL), the leader in predictive diagnostics for diabetic kidney disease, presents a comprehensive update on the commercialisation progress for its PromarkerD test.
KEY TAKEAWAYS:
- PromarkerD rated the world’s leading diagnostic test for diabetic kidney disease by global market research firm Frost & Sullivan;
- First licensing income received;
- Key patents secured and extended;
- Clinical laboratory prototype manufacture on target for mid-2017;
- First commercial sales are targeted for the end of 2017;
- Validation study completed – announcement of results pending publication of the prior predictive development study;
- Development study shows PromarkerD correctly predicts 95% of otherwise healthy diabetics who will develop chronic kidney disease;
- Discussions continue with prospective diagnostic companies in the USA, China, Europe, Australia and Japan to secure licences for the commercialisation of PromarkerD.
PromarkerD is a predictive diagnostic test for diabetic kidney disease. In a clinical study PromarkerD correctly predicted 95% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. PromarkerD was last month rated the world’s leading diagnostic test for diabetic kidney disease in the Frost & Sullivan report Biomarkers Enabling Diabetes and Obesity Management.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
